Novabay Pharmaceuticals Inc Prix / Ventes
Quel est le Prix / Ventes de Novabay Pharmaceuticals Inc?
Le Prix / Ventes de Novabay Pharmaceuticals Inc est 0.27
Quelle est la définition de Prix / Ventes?
Le rapport prix / ventes est le prix des actions d'une entreprise par rapport à ses revenus.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Prix / Ventes des entreprises dans Health Care secteur sur NYSEMKT par rapport à Novabay Pharmaceuticals Inc
Que fait Novabay Pharmaceuticals Inc?
novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across
Entreprises avec prix / ventes similaire à Novabay Pharmaceuticals Inc
- Walgreens Boots Alliance a Prix / Ventes de 0.27
- Service Stream a Prix / Ventes de 0.27
- Saturn Oil & Gas a Prix / Ventes de 0.27
- eHealth Inc a Prix / Ventes de 0.27
- Plastic Omnium SA a Prix / Ventes de 0.27
- Ford Motor Co a Prix / Ventes de 0.27
- Novabay Pharmaceuticals Inc a Prix / Ventes de 0.27
- Munjal Auto Industries a Prix / Ventes de 0.27
- JD Wetherspoon Plc a Prix / Ventes de 0.27
- Digital Wine Ventures a Prix / Ventes de 0.27
- Kawasaki Heavy Industries a Prix / Ventes de 0.27
- UET United Electronic Technology AG a Prix / Ventes de 0.27
- China Glass a Prix / Ventes de 0.27